Insulet (PODD) Upgraded at BidaskClub
Other analysts also recently issued reports about the company. Northland Securities restated a “buy” rating and issued a $100.00 price objective on shares of Insulet in a report on Tuesday, February 26th. Canaccord Genuity increased their price target on Insulet from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, February 19th. ValuEngine downgraded Insulet from a “strong-buy” rating to a “buy” rating in a research note on Monday, January 7th. Morgan Stanley reduced their target price on Insulet from $105.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Finally, Oppenheimer set a $100.00 price target on shares of Insulet and gave the company a “hold” rating in a research report on Tuesday, February 26th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $103.20.
Insulet stock opened at $86.08 on Wednesday. Insulet has a 12 month low of $70.80 and a 12 month high of $108.90. The company has a debt-to-equity ratio of 2.79, a quick ratio of 3.37 and a current ratio of 3.99. The company has a market capitalization of $5.14 billion, a PE ratio of 1,721.60 and a beta of 1.51.
In other Insulet news, insider Shacey Petrovic sold 1,066 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $92.64, for a total value of $98,754.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP David Colleran sold 7,395 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $94.89, for a total transaction of $701,711.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 87,138 shares of company stock worth $8,140,640. Corporate insiders own 3.50% of the company’s stock.
Several large investors have recently modified their holdings of PODD. Norges Bank bought a new stake in shares of Insulet in the 4th quarter worth about $53,604,000. First Trust Advisors LP grew its position in Insulet by 103.6% during the 4th quarter. First Trust Advisors LP now owns 458,028 shares of the medical instruments supplier’s stock worth $36,331,000 after purchasing an additional 233,075 shares during the last quarter. Standard Life Aberdeen plc purchased a new stake in Insulet during the 4th quarter worth approximately $16,011,000. Teachers Advisors LLC lifted its stake in shares of Insulet by 105.8% in the 3rd quarter. Teachers Advisors LLC now owns 326,021 shares of the medical instruments supplier’s stock valued at $34,542,000 after purchasing an additional 167,598 shares during the period. Finally, KAMES CAPITAL plc lifted its stake in shares of Insulet by 22.7% in the 1st quarter. KAMES CAPITAL plc now owns 582,252 shares of the medical instruments supplier’s stock valued at $55,372,000 after purchasing an additional 107,828 shares during the period.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Recommended Story: Convertible Shares
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.